M&T Bank’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

M&T Bank’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-889	Closed	-$149K	–	1605
2020 Q2	$149K	Hold	889	–	–	﹤0.01%	1421
2020 Q1	$62K	Hold	889	–	–	﹤0.01%	1463
2019 Q4	$57K	Hold	889	–	–	﹤0.01%	1336
2019 Q3	$52K	Hold	889	–	–	﹤0.01%	1529
2019 Q2	$53K	Hold	889	–	–	﹤0.01%	1529
2019 Q1	$58K	Hold	889	–	–	﹤0.01%	1515
2018 Q4	$47K	Hold	889	–	–	﹤0.01%	1377
2018 Q3	$51K	Hold	889	–	–	﹤0.01%	1485
2018 Q2	$52K	Hold	889	–	–	﹤0.01%	1488
2018 Q1	$42K	Hold	889	–	–	﹤0.01%	1505
2017 Q4	$52K	Hold	889	–	–	﹤0.01%	1499
2017 Q3	$55K	Hold	889	–	–	﹤0.01%	1496
2017 Q2	$55K	Hold	889	–	–	﹤0.01%	1486
2017 Q1	$57K	Hold	889	–	–	﹤0.01%	1529
2016 Q4	$34K	Hold	889	–	–	﹤0.01%	1595
2016 Q3	$32K	Hold	889	–	–	﹤0.01%	1612
2016 Q2	$32K	Hold	889	–	–	﹤0.01%	1585
2016 Q1	$36K	Hold	889	–	–	﹤0.01%	1612
2015 Q4	$38K	Hold	889	–	–	﹤0.01%	1626
2015 Q3	$31K	Hold	889	–	–	﹤0.01%	1713
2015 Q2	$48K	Sell	889 -667	-43%	-$39.8K	﹤0.01%	1943
2015 Q1	$104K	Hold	1,556	–	–	﹤0.01%	1841
2014 Q4	$111K	Buy	+1,556	New	+$81.7K	﹤0.01%	1860

Other funds holding BCLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

AHB

Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

M&T Bank's BCLI Position: Q3 2020 in Review

M&T Bank sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2020, closing a stake of 889 shares — an estimated $149K sold.

M&T Bank first reported a position in BCLI in Q4 2014 and held it in 23 quarters. The position peaked at $149K in Q2 2020. 80 funds tracked by Wall St. Rank hold BCLI as of Q3 2020.

M&T Bank reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2020 after selling out during the quarter.
M&T Bank sold 889 BRAINSTORM CELL THERAPUTC shares in Q3 2020, an estimated $149K.
M&T Bank first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2014 and held it in 23 quarters.
M&T Bank's BRAINSTORM CELL THERAPUTC position peaked at $149K in Q2 2020.
80 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2020.

Based on M&T Bank's 13F filing for Q3 2020, filed 6 Nov 2020.